Global Merkel Cell Carcinoma Treatment Market Overview
Merkel Cell Carcinoma Market Size was valued at USD 0.43 Billion in 2023. The Global Merkel Cell Carcinoma industry is projected to grow from USD 1.02 Billion in 2024 to USD 4.12 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.65% during the forecast period (2024 - 2032).The very aggressive skin cancer Merkel Cell Carcinoma (MCC), also known as neuroendocrine carcinoma, is extremely uncommon (approximately forty times less likely to occur than the somewhat less uncommon and better-known malignant melanoma).
The Merkel cell polyomavirus (MCPyV or MCV), which causes Merkel cell cancer, typically first manifests as a single, painless lump on sun-exposed skin. Although the particular cause of merkel cell carcinoma is unknown, those who have a history of other skin malignancies or excessive sun exposure, as well as people who are older and have low immune systems, are at higher risk of developing the disease. It is crucial to the healthcare industry, so it is predicted to grow significantly during the forecast period.
The market for merkel cell cancer therapies is expected to grow significantly throughout the projected period. After melanoma, Merkel cell carcinoma is the most lethal kind of skin cancer. Excessive sun exposure and immune system dysfunction are the primary causes of this cancer. Growth in the treatment of merkel cell cancer has been bolstered by positive reimbursement policies and robust use of immunotherapy. Rising cancer rates, improved access to healthcare, rising levels of ultraviolet radiation due to pollution and climate change, rising rates of immunosuppression, and rising numbers of newly diagnosed cancer patients all point to a bright future for the merkel cell carcinoma therapeutics market.
Growth in the global market for merchandising and distribution services is predicted to be driven by a number of factors, including rising spending on pharmaceuticals in developing countries, an increasing focus on "patient-centric" care that is expected to spur innovation regarding effective drugs and revolutionize technological advances in research and development, and significant unmet needs that are expected to encourage the emergence of a new market entrant and the widespread adoption of novel therapies.
August 2023: Clinical data from the Company's ongoing Phase 2 study of VP-315 for the treatment of basal cell carcinoma will be presented in an abstract accepted by the American Society for Dermatologic Surgery in August 2023. Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Clinical and histological clearance of treated BCC lesions from the current Phase 2 study by the Company were emphasized at the announcement as evidence of the anticancer activity of VP-315.
COVID-19 Impact Analysis
All businesses have been significantly affected by the current Covid-19 outbreak. Medical aid was in short supply in the healthcare industry due to a lack of beds to meet the demands of the expanding patient population. The majority of businesses are inactive, and those located close to consumers' homes are barely able to handle sales, which is producing fluctuations in the global economy. The pandemic COVID-19 had a negative impact on the treatment of intestinal cancer, which can negatively affect patients' overall and disease-free survival. The number of referrals for intestinal cancer treatment has dramatically decreased as a result of the drop in COVID-19 patients.
During the anticipated timeframe, there will likely be a significant expansion in the market for treatments for merkel cell cancer. Merkel cell carcinoma is the most common type of skin cancer after melanoma fatality after melanoma. A compromised immune system and excessive sun exposure are the main causes of this malignancy. Positive reimbursement and strong immunotherapy uptake are optimistic signs for merkel cell cancer treatment growth. The market for merkel cell carcinoma therapeutics is expected to expand due to a number of factors, including the rising incidence of cancer, better health insurance coverage, increased UV exposure from pollution and global warming, a higher prevalence of immunosuppression that causes more cancer cases, and increased research and development of therapeutics.
Market Drivers
The increasing incidence of merkel cell cancer
Among the major factors driving the worldwide market is the disease's increasing prevalence. An article in the Current Dermatology Reports journal estimated that MCC affects about 0.6 of every 100,000 people annually. According to the National Cancer Database, there are approximately 2500, and 1500 new MCC cases reported year in the US and European regions, respectively. The market is anticipated to grow as a result of expanding research and development efforts for the treatment of merkel cell carcinoma. Surgery is frequently used as the initial treatment for patients with merkel cell cancer.
Market Restraints
The negative consequences of external radiation therapy will limit market expansion
External radiation therapy can, however, have certain negative side effects, such as skin changes, nausea, diarrhea, exhaustion, severe mouth and throat ulcers, and dry mouth or thick saliva. The radiation's negative effects are transient, but very rarely, major side effects can last a lifetime. Radiation to the chest can occasionally damage the lungs, which can cause breathing issues and shortness of breath
Market Opportunities
The rise in investment in treatment
Increasing pharmaceutical investment from developing nations, a growing emphasis on "patient-centric" care, which is anticipated to foster innovation regarding effective drugs, revolutionize technological advancements in research and development, and high unmet needs, which is anticipated to lead to the entry of a new player and increase in acceptance of newer treatments, and technological advancements are all factors that are expected to propel the global market for merkel cell carcinoma treatment over the projected period.
Based on segment, the market has been divided into surgery, radiation therapy, and chemotherapy. The global market for merkel cell carcinoma treatment growth was prominently high under the radiation therapy segment held a major share in 2021. Due to clinical trials being conducted by the major players, radiation treatment is anticipated to grow in the market over the upcoming years. High doses of radiation are used in radiation therapy, also known as radiotherapy, as a cancer treatment to eradicate cancer cells and reduce tumor size. As with x-rays of teeth or fractured bones, radiation is utilized at low levels in x-rays to see within the body. Cancer cells are not quickly destroyed by radiation therapy. Days or weeks of treatment are needed before the DNA damage is sufficient to kill cancer cells. Cancer cells continue to die for a few weeks or months after radiation therapy is finished
Based on treatment, the Merkel Cell Carcinoma Treatment Market segment has been divided into surgery, radiation therapy, and chemotherapy. The global market growth was prominently high under the chemotherapy segment held a major share in 2021. The rise of the chemotherapy sector in the worldwide Merkel cell carcinoma treatments market is anticipated to be aided by doctors' preference for chemotherapy drugs in the treatment of cancer.
Based on end-user, the Merkel Cell Carcinoma Treatment Market segmentation has been divided into hospitals & clinics, and diagnostic centers. The Merkel Cell Carcinoma Treatment Market growth was prominently high under the hospitals & clinics segment held a major share in 2021 because there are many facilities in one place and cutting-edge technology is readily available.
March 2023: The FDA has approved Zynyz, an injectable medication developed by Incyte, in March 2023. The Merkel cell carcinoma (MCC) medication was approved by the FDA under the rapid approval procedure for the treatment of patients with metastatic disease or recurrent locally progressed disease. Zynyz is an immunotherapy that works by inhibiting the PD-1 checkpoint. Along with Merck & Co.'s PD-1 inhibitor Keytruda and Pfizer and Merck KGaA's PD-L1 aimed Bavencio, it is the eighth checkpoint inhibitor to receive FDA approval and the third intended for metastatic MCC. The POD1UM-201 trial provided the basis for the approval, as it was a single-arm evaluation of the medicine in adults who had never had systemic treatment before.
By region, the Merkel Cell Carcinoma Treatment Market has been divided into North America, Europe, Asia-Pacific, and the Rest of the World. North America accounted for the most extensive market share. Europe is projected to exhibit the highest CAGR during the review period.
North America was the most extensive market for merkel cell carcinoma treatment share in 2021 due to the presence of advanced economies like the United States and Canada, a strong healthcare industry, and high per capita healthcare costs. Additionally, market growth is boosted by the presence of the leading industry players in the area.
Europe is anticipated to encounter the fastest growth rate during the forecast period. The availability of research funding, the sizeable patient population, and government backing for R&D are predicted to propel market expansion in the area. In addition, the rising number of skin cancer patients creates excellent conditions for market expansion in the area.
Merkel Cell Carcinoma Treatment Market Competitive Landscape
The market includes tier-1, tier-2, and local players. The key market participants generally pursue the new market for merkel cell carcinoma treatment categories. In manufacturing, specialized robots programmed for a particular work environment are generally preferable to the market for merkel cell carcinoma treatment. Investment is anticipated to strengthen the company's leadership in market for merkel cell carcinoma treatment because more money is being invested in updating and replacing deteriorating grid infrastructure.
Key Players
Key players in the Merkel Cell Carcinoma Treatment Market research include
Physical Examination
Sentinel Node Biopsy
Imaging Test
Surgery
Radiation Therapy
Chemotherapy
Cans
Pouches/Sachets
North America
US
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
India
Japan
Australia and New Zealand
Rest of Asia-Pacific
Rest of the World
South America
Middle East
Africa
Objectives of the Study
The objectives of the study are summarized in 5 stages. They are as mentioned below:
Merkel Cell Carcinoma Treatment Market Forecast & Size:
To identify and estimate the market size for the Merkel Cell Carcinoma Treatment Market report segmented by product, type, power rating and end-use by value (in US dollars). Also, to understand the consumption/ demand created by consumers of Merkel Cell Carcinoma Treatment Market forecast between 2024 and 2032
Market Landscape and Trends:
To identify the Merkel Cell Carcinoma Treatment Market growth and infer the drivers, restraints, opportunities, and challenges.
Market Influencing Factors:
To find out the factors which are affecting the Merkel Cell Carcinoma Treatment Market size
Impact of COVID-19:
To identify and understand the various factors involved in the market affected by the pandemic
Company Profiling:
To provide a detailed insight into the major companies operating in the market. The profiling will include the financial health of the company in the past 2-3 years with segmental and regional revenue breakup, product offering, recent developments, SWOT analysis, and key strategies.
Intended Audience
Manufacturers
Raw material suppliers
Retailers, wholesalers, and distributors
Governments, associations, and industrial bodies
Investors and Trade Experts
| Report Attribute/Metric | Details |
| Market Size | 4.12 Billion (2024-2032) |
| CAGR | 4.65%: 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2022 |
| Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | By Diagnosis, by Treatment, by End User |
| Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Key Vendors | Pfizer Inc. (U.S.), Merck & Co., Inc. (U.S.), OncoSec Medical Incorporated (U.S.), Bristol-Myers Squibb Company (U.S.), General Electric Company (U.S.), Siemens Medical Solutions USA, Inc. (Germany), CANON MEDICAL SYSTEMS CORPORATION (Japan), Philips Health Care (The Netherlands), AstraZeneca |
| Key Market Opportunities | high cost of therapeutics and related side effects, lack of awareness, and low per capita healthcare expenditures |
| Key Market Drivers | growing geriatric population, and rising healthcare expenditure |
Merkel Cell Carcinoma Market Highlights:
Frequently Asked Questions (FAQ) :
The Merkel Cell Carcinoma Treatment Market forecast period is 2024 - 2032
The market is expected to register a CAGR of 4.65% over the next 10 years, according to the Merkel Cell Carcinoma Treatment Market research.
Europe is expected to register the highest CAGR during 2024-2032
North America held the largest share in 2021
The market size is expected to be USD 4.12 billion by 2032.
Merck & Co., OncoSec Medical Incorporated (U.S.), Bristol-Myers Squibb Company (U.S.), General Electric Company (U.S.), Siemens Medical Solutions USA CANON MEDICAL SYSTEMS CORPORATION are the major companies operating in the global market.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
